Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study
| Autor: | Lars Gullestad, Magne Følling, Elin Kjekshus, J G Fjeld, Arne Yndestad, Even Holt, John Kjekshus, Ragnhild Wergeland, Rita Skårdal, Stig S. Frøland, Anders Hodt, Thor Ueland, Anne Grete Semb, Kjell Breivik, Pål Aukrust, Arne K. Andreassen, Torstein Gundersen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cardiomyopathy
Dilated medicine.medical_specialty Heart disease Cardiomyopathy In Vitro Techniques Placebo Coronary artery disease Placebos Ventricular Dysfunction Left Double-Blind Method Physiology (medical) Internal medicine Idiopathic dilated cardiomyopathy Medicine Humans Aged Heart Failure Ejection fraction Tissue Inhibitor of Metalloproteinase-1 Dose-Response Relationship Drug business.industry Tumor Necrosis Factor-alpha Interleukin-8 Middle Aged medicine.disease Surgery Thalidomide Heart failure Immune System Cardiology Matrix Metalloproteinase 2 Female Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
| Zdroj: | Circulation. 112(22) |
| ISSN: | 1524-4539 |
| Popis: | Background—Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD).Methods and Results—Fifty-six patients with CHF and an LV ejection fraction (LVEF) Conclusions—Although our results must be confirmed in larger studies that also examine the effects on morbidity and mortality, our findings suggest a role for thalidomide in the management of CHF in addition to traditional cardiovascular medications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|